These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 35401164)

  • 21. Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain: current development.
    Wen MM
    Discov Med; 2011 Jun; 11(61):497-503. PubMed ID: 21712015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery.
    Maher R; Moreno-Borrallo A; Jindal D; Mai BT; Ruiz-Hernandez E; Harkin A
    Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Agile delivery of protein therapeutics to CNS.
    Yi X; Manickam DS; Brynskikh A; Kabanov AV
    J Control Release; 2014 Sep; 190():637-63. PubMed ID: 24956489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current non-invasive strategies for brain drug delivery: overcoming blood-brain barrier transport.
    Zheng X; Yang J; Hou Y; Fang Y; Wu K; Song Y; Liu K; Zhu J
    Mol Biol Rep; 2023 Dec; 51(1):25. PubMed ID: 38127178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Traditional neurotherapeutics approach intended for direct nose to brain delivery.
    Abolhasanzadeh Z; Ashrafi H; Badr P; Azadi A
    J Ethnopharmacol; 2017 Sep; 209():116-123. PubMed ID: 28733193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting.
    Pardeshi CV; Belgamwar VS
    Expert Opin Drug Deliv; 2013 Jul; 10(7):957-72. PubMed ID: 23586809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Delivery Systems and Strategies to Overcome the Barriers of Brain.
    Garg Y; Kapoor DN; Sharma AK; Bhatia A
    Curr Pharm Des; 2022; 28(8):619-641. PubMed ID: 34951356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Dual Therapy of Nanostructured Lipid Carrier Loaded with Teriflunomide-A Dihydro-Orotate Dehydrogenase Inhibitor and an miR-155-Antagomir in Cuprizone-Induced C57BL/6J Mouse.
    Koduru TS; Gupta VN; Veeranna B; Seetharaman S
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.
    Islam SU; Shehzad A; Ahmed MB; Lee YS
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.
    Dhuria SV; Hanson LR; Frey WH
    J Pharm Sci; 2009 Jul; 98(7):2501-15. PubMed ID: 19025760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Routes for the delivery of insulin to the central nervous system: A comparative review.
    Rhea EM; Salameh TS; Banks WA
    Exp Neurol; 2019 Mar; 313():10-15. PubMed ID: 30500332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges.
    Chatterjee B; Gorain B; Mohananaidu K; Sengupta P; Mandal UK; Choudhury H
    Int J Pharm; 2019 Jun; 565():258-268. PubMed ID: 31095983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis.
    Mwema A; Muccioli GG; des Rieux A
    J Control Release; 2023 Dec; 364():435-457. PubMed ID: 37926243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perivascular and Perineural Pathways Involved in Brain Delivery and Distribution of Drugs after Intranasal Administration.
    Lochhead JJ; Davis TP
    Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31726721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
    Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
    Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal administration of CNS therapeutics to awake mice.
    Hanson LR; Fine JM; Svitak AL; Faltesek KA
    J Vis Exp; 2013 Apr; (74):. PubMed ID: 23608783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review.
    Kulkarni M; Patel K; Patel A; Patel S; Desai J; Patel M; Shah U; Patel A; Solanki N
    ADMET DMPK; 2024; 12(1):63-105. PubMed ID: 38560713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs.
    Mignani S; Shi X; Karpus A; Majoral JP
    Eur J Med Chem; 2021 Jan; 209():112905. PubMed ID: 33069435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.
    Mahajan HS; Mahajan MS; Nerkar PP; Agrawal A
    Drug Deliv; 2014 Mar; 21(2):148-54. PubMed ID: 24128122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.